Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 39

1.

Rho GDP dissociation inhibitor-β in renal cell carcinoma.

von Klot CA, Dubrowinskaja N, Peters I, Hennenlotter J, Merseburger AS, Stenzl A, Kuczyk MA, Serth J.

Oncol Lett. 2017 Dec;14(6):8190-8196. doi: 10.3892/ol.2017.7233. Epub 2017 Oct 20.

2.

To Excavate Biomarkers Predictive of the Response for Capecitabine plus RAD001 through Nanostring-Based Multigene Assay in Advanced Gastric Cancer Patients.

Lee H, Lee J, Sohn I, Park SH, Park JO, Park YS, Kim KM, Kang WK, Kim ST.

J Cancer. 2016 Oct 25;7(15):2173-2178. eCollection 2016.

3.

Targeting the Phosphatidylinositol-3-kinase Pathway in Gastric Cancer: Can Omics Improve Outcomes?

Tran P, Nguyen C, Klempner SJ.

Int Neurourol J. 2016 Nov;20(Suppl 2):S131-140. Epub 2016 Nov 22. Review.

4.

Autocrine MCP-1/CCR2 signaling stimulates proliferation and migration of renal carcinoma cells.

Küper C, Beck FX, Neuhofer W.

Oncol Lett. 2016 Sep;12(3):2201-2209. Epub 2016 Jul 18.

5.

Role of mTOR Inhibitors in Kidney Disease.

Kajiwara M, Masuda S.

Int J Mol Sci. 2016 Jun 21;17(6). pii: E975. doi: 10.3390/ijms17060975. Review.

6.

Systemic therapy in metastatic renal cell carcinoma.

Bedke J, Gauler T, Grünwald V, Hegele A, Herrmann E, Hinz S, Janssen J, Schmitz S, Schostak M, Tesch H, Zastrow S, Miller K.

World J Urol. 2017 Feb;35(2):179-188. doi: 10.1007/s00345-016-1868-5. Epub 2016 Jun 9. Review.

7.

Tivozanib: a novel VGFR inhibitor for kidney cancer.

Boyle H.

Transl Androl Urol. 2013 Jun;2(2):114-6. doi: 10.3978/j.issn.2223-4683.2012.07.04.

8.

Increased Insulin mRNA Binding Protein-3 Expression Correlates with Vascular Enhancement of Renal Cell Carcinoma by Intravenous Contrast-CT and is Associated with Bone Metastasis.

Xie C, Li Y, Li Q, Chen Y, Yao J, Yin G, Bi Q, O'Keefe RJ, Schwarz EM, Tyler W.

J Bone Oncol. 2015 Sep;4(3):69-76. Epub 2015 Sep 12.

9.

Decreased expression of CHIP leads to increased angiogenesis via VEGF-VEGFR2 pathway and poor prognosis in human renal cell carcinoma.

Sun C, Li HL, Chen HR, Shi ML, Liu QH, Pan ZQ, Bai J, Zheng JN.

Sci Rep. 2015 May 29;5:9774. doi: 10.1038/srep09774.

10.

RLIP76 Targeted Therapy for Kidney Cancer.

Singhal SS, Singhal J, Figarola J, Horne D, Awasthi S.

Pharm Res. 2015 Oct;32(10):3123-36. doi: 10.1007/s11095-015-1723-1. Epub 2015 May 29. Review.

11.

TCDD induces the hypoxia-inducible factor (HIF)-1α regulatory pathway in human trophoblastic JAR cells.

Liao TL, Chen SC, Tzeng CR, Kao SH.

Int J Mol Sci. 2014 Sep 30;15(10):17733-50. doi: 10.3390/ijms151017733.

12.

NFAT5-mediated expression of S100A4 contributes to proliferation and migration of renal carcinoma cells.

Küper C, Beck FX, Neuhofer W.

Front Physiol. 2014 Aug 8;5:293. doi: 10.3389/fphys.2014.00293. eCollection 2014.

13.
14.

Scoring docking conformations using predicted protein interfaces.

Esmaielbeiki R, Nebel JC.

BMC Bioinformatics. 2014 Jun 6;15:171. doi: 10.1186/1471-2105-15-171.

15.

A RAS renaissance: emerging targeted therapies for KRAS-mutated non-small cell lung cancer.

Vasan N, Boyer JL, Herbst RS.

Clin Cancer Res. 2014 Aug 1;20(15):3921-30. doi: 10.1158/1078-0432.CCR-13-1762. Epub 2014 Jun 3. Review.

16.

PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies.

Lee JM, Ledermann JA, Kohn EC.

Ann Oncol. 2014 Jan;25(1):32-40. doi: 10.1093/annonc/mdt384. Epub 2013 Nov 12. Review.

17.

Two cases of recurrent ovarian clear cell carcinoma treated with sorafenib.

Koshiyama M, Matsumura N, Baba T, Yamaguchi K, Yoshioka Y, Konishi I.

Cancer Biol Ther. 2014 Jan;15(1):22-5. doi: 10.4161/cbt.26608. Epub 2013 Oct 21.

18.

Polymorphisms in the mTOR gene and risk of sporadic prostate cancer in an Eastern Chinese population.

Li Q, Gu C, Zhu Y, Wang M, Yang Y, Wang J, Jin L, Zhu ML, Shi TY, He J, Zhou X, Ye DW, Wei Q.

PLoS One. 2013 Aug 5;8(8):e71968. doi: 10.1371/journal.pone.0071968. Print 2013. Erratum in: PLoS One. 2014;9(1). doi:10.1371/annotation/bc36c048-60e4-48a2-908d-6253e93df062.

19.

Efficacy of temsirolimus in metastatic chromophobe renal cell carcinoma.

Venugopal B, Ansari J, Aitchison M, Tho LM, Campbell R, Jones RJ.

BMC Urol. 2013 May 21;13:26. doi: 10.1186/1471-2490-13-26.

20.

A polymorphism (rs2295080) in mTOR promoter region and its association with gastric cancer in a Chinese population.

Xu M, Tao G, Kang M, Gao Y, Zhu H, Gong W, Wang M, Wu D, Zhang Z, Zhao Q.

PLoS One. 2013;8(3):e60080. doi: 10.1371/journal.pone.0060080. Epub 2013 Mar 29.

Supplemental Content

Support Center